Back

Impaired ICOS signaling between Tfh and B cells distinguishes hospitalized from ambulatory CoViD-19 patients

Hanson, A.; Cohen, H.; Wang, H.; Shekhar, N.; Shah, C.; Dhaneshwar, A.; Harvey, B. W.; Murray, R.; Harvey, C. J.

2020-12-18 infectious diseases
10.1101/2020.12.16.20248343
Show abstract

Emerging evidence suggests that SARS-CoV-2 infections are characterized by systemic immune responses that appear to be dysregulated with more severe CoViD-19 disease. Lymphopenia and delayed antibody responses are commonly identified in CoViD-19 subjects, and recent reports have demonstrated abrogation of germinal centers in severe CoViD-19. This work assessed a potential mechanistic basis for impaired humoral responses, focusing on the T follicular helper (Tfh) and B cell interface that is critical for germinal center reactions. Here we demonstrated that Tfh activity is impaired in hospitalized relative to ambulatory CoViD-19 subjects, potentially due to decreased expression of the costimulatory molecule ICOS-L on B cells. Functional impairment manifested as a diminished ability to stimulated Tfh derived IFN{gamma} and IL-21, the latter of which is critical for B cell proliferation and differentiation. Activation of Tfh cells by agonism of the ICOS receptor ex vivo by an agonistic antibody stimulated the generation of IFN{gamma}/IL-21 double positive cells from hospitalized CoViD-19 subjects. This report establishes an immunological defect that differentiates ambulatory from hospitalized CoViD and suggests that agents that could restore impaired mechanisms at the Tfh-B cell interface may be of therapeutic value.

Matching journals

The top 8 journals account for 50% of the predicted probability mass.

1
JCI Insight
based on 63 papers
Top 0.1%
13.1%
2
Journal of Clinical Investigation
based on 50 papers
Top 0.2%
7.5%
3
Nature Communications
based on 483 papers
Top 13%
6.3%
4
Science Immunology
based on 15 papers
Top 0.1%
5.7%
5
Cell
based on 28 papers
Top 0.2%
5.2%
6
Cell Reports Medicine
based on 49 papers
Top 0.5%
5.0%
7
Nature Immunology
based on 14 papers
Top 0.2%
4.4%
8
The Journal of Immunology
based on 19 papers
Top 0.3%
4.4%
50% of probability mass above
9
Clinical & Translational Immunology
based on 14 papers
Top 0.1%
4.4%
10
Science Translational Medicine
based on 40 papers
Top 1%
2.9%
11
Immunity
based on 11 papers
Top 0.2%
2.8%
12
Nature Medicine
based on 88 papers
Top 3%
2.8%
13
Cell Reports
based on 25 papers
Top 0.4%
2.5%
14
Frontiers in Immunology
based on 140 papers
Top 3%
2.5%
15
Nature
based on 58 papers
Top 4%
2.3%
16
iScience
based on 74 papers
Top 3%
1.7%
17
PLOS ONE
based on 1737 papers
Top 88%
1.7%
18
PLOS Pathogens
based on 35 papers
Top 1.0%
1.6%
19
Proceedings of the National Academy of Sciences
based on 100 papers
Top 8%
1.6%
20
eLife
based on 262 papers
Top 23%
1.3%
21
Journal of Experimental Medicine
based on 10 papers
Top 0.6%
1.3%
22
The Journal of Infectious Diseases
based on 137 papers
Top 8%
1.3%
23
Science
based on 46 papers
Top 5%
1.3%
24
mBio
based on 34 papers
Top 2%
1.2%
25
Clinical Infectious Diseases
based on 219 papers
Top 20%
0.8%
26
Journal of Clinical Immunology
based on 11 papers
Top 0.7%
0.8%
27
eBioMedicine
based on 82 papers
Top 9%
0.7%
28
Clinical Immunology
based on 12 papers
Top 2%
0.7%